Selective ETAAntagonists. 5. Discovery and Structure−Activity Relationships of Phenoxyphenylacetic Acid Derivatives
Citations Over TimeTop 23% of 2000 papers
Abstract
The fifth paper in this series describes the culmination of our investigations into the development of a potent and selective ET(A) receptor antagonist for the treatment of diseases mediated by ET-1. Receptor site mapping of several ET(A) antagonists prepared previously identified a common cationic binding site which prompted synthesis of phenoxyphenylacetic acid derivative 13a, which showed good in vitro activity (IC(50) 59 nM, rat aortic ET(A)). Optimization of 13a led to the identification of 27b, which exhibited an IC(50) of 4 nM. Although this did not translate into the expected in vivo potency, a compound of comparable in vitro activity, 27a (RPR118031A), showed a far better pharmacokinetic profile and in vivo potency (75 micromol/kg) and was duly proposed and accepted as a development candidate.
Related Papers
- → Structure–activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist(2001)40 cited
- → Design, synthesis, and biological evaluation of novel diarylalkyl amides as TRPV1 antagonists(2009)13 cited
- → Quantitative Structure-Activity Relationships of 5-Lipoxygenase Inhibitors. Inhibitory Potency of Pyridazinone Analogues(1994)13 cited
- → The synthesis of heterosubstituted benzimidazole derivatives with potent angiotensin II antagonist activity(1993)5 cited
- → Synthesis and biological activity of the platelet-activating factor antagonist (±)-trans-2-(3-methoxy-4-phenylsulfonylethoxy-5-n-propylsulfonylphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-671,284) and its analogs(1992)6 cited